- Open Access
Letter to the Editor: A response to Hruska’s case study on molecular breast imaging and the need for true tissue quantification
Breast Cancer Research volume 21, Article number: 15 (2019)
We applaud the efforts by Hruska et al.  to quantify differences in tissue using molecular breast imaging (MBI) and background parenchymal uptake (BPU); we have discussed the use of such previously . The approach while commendable did not provide diagnostically useful information to differentiate tissue types. This approach, like the utilization of standardized uptake value (SUV), compares differences in background with tissue . As we have already discussed [2, 4, 5] in the literature, this approach is an incorrect model, due to (1) the critical lack of standardization and calibration of nuclear cameras including both SPECT/Planar and PET; (2) the utilization of ratios which are not absolute values and therefore cannot be used to differentiate tissue based upon those issues, issues which are critical to the understanding of tissue differences; and (3) the inability to truly “measure” transitional changes in tissue, which would allow for the determination of actual treatment response on a per patient basis, saving time, money, and lives.
Hruska CB, Geske JR, Swanson TN, et al. Quantitative background parenchymal uptake on molecular breast imaging and breast cancer risk: a case-control study. Breast Cancer Res. 2018;20:46. https://doi.org/10.1186/s13058-018-0973-3.
Fleming RM, Dooley WC. Breast enhanced scintigraphy testing (B.E.S.T.) distinguishes between normal, inflammatory breast changes and breast cancer. A prospective analysis and comparison with mammography. Integr Cancer Ther. 2002;1(3):238–45.
Keys JW Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836–9.
Fleming RM, Fleming MR, McKusick A, Chaudhuri TK. Semiquantification limitations: FMTVDM©℗ demonstrates quantified tumor response to treatment with both regional blood flow and metabolic changes. J Nucl Med. 2018;59(10):1643–4. https://doi.org/10.2967/jnumed.118.217018 published ahead of print. PMID: 30030345.
Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC, McKusick A. FMTVDM; B.E.S.T.©℗ imaging theranostically used to guide treatment response in a woman with recalcitrant breast cancer. Biomed J Sci Tech Res. 2018 ISSN: 2574-1241. DOI: https://doi.org/10.26717/BJSTR.2018.11.002111.
Availability of data and materials
Not applicable. All patent material is proprietary and require licensure.
Included on cover sheet.
Ethics approval and consent to participate
Consent for publication
Consent granted by all authors.
The patent was issued to the primary author by the USPTO. The other authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Fleming, R.M., Fleming, M.R., Chaudhuri, T.K. et al. Letter to the Editor: A response to Hruska’s case study on molecular breast imaging and the need for true tissue quantification. Breast Cancer Res 21, 15 (2019). https://doi.org/10.1186/s13058-019-1103-6
- FMTVDM©℗; B.E.S.T. Imaging©℗
- Breast cancer
- Breast inflammation
- Nuclear camera quantitative calibration
- Patent protected